TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3

Carcinogenesis

Volumn 37, Issue 11, 2016, Pages 1041-1051

  Hesler, Rachel A ^a   Huang, Jennifer J ^a   Starr, Mark D ^a   Treboschi, Victoria M ^a   Bernanke, Alyssa G ^a   Nixon, Andrew B ^a   McCall, Shannon J ^a   White, Rebekah R ^a   Blobe, Gerard C ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE RICH PROTEIN 61; GEMCITABINE; NUCLEOSIDE TRANSPORTER; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC ANTIMETABOLITE; CARRIER PROTEIN; CIF NUCLEOSIDE TRANSPORTER; CYR61 PROTEIN, HUMAN; DEOXYCYTIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; SLC29A1 PROTEIN, HUMAN;

ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PANCREAS ADENOCARCINOMA; PANCREATIC STELLATE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CASE CONTROL STUDY; COCULTURE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; NONPARAMETRIC TEST; PANCREATIC NEOPLASMS; PHYSIOLOGY; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYSTEINE-RICH PROTEIN 61; DEOXYCYTIDINE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE TRANSPORT PROTEINS; PANCREATIC NEOPLASMS; PANCREATIC STELLATE CELLS; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84994519248     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgw093     Document Type: Article

References (61)

1. Siegel, R. et al. (2014) Cancer statistics, 2014. CA: A Cancer J. Clin., 64, 9-29.
2. Rahib, L. et al. (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res., 74, 2913-2921.
3. de Sousa Cavalcante, L. et al. (2014) Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur. J. Pharmacol., 741, 8-16.
4. Burris, H.A. 3rd et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 15, 2403-2413.
5. Garrido-Laguna, I. et al. (2015) Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat. Rev. Clin. Oncol., 12, 319-334.
6. Gray, J.H. et al. (2004) The concentrative nucleoside transporter family, SLC28. Pflugers. Arch., 447, 728-734.
7. Baldwin, S.A. et al. (2004) The equilibrative nucleoside transporter family, SLC29. Pflugers. Arch., 447, 735-743.
8. Paproski, R.J. et al. (2013) Human concentrative nucleoside transporter 3 transfection with ultrasound and microbubbles in nucleoside transport deficient HEK293 cells greatly increases gemcitabine uptake. PLoS One, 8, e56423.
9. Fujita, H. et al. (2010) Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia, 12, 807-817.
10. Maréchal, R. et al. (2012) Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology, 143, 664-674.e1.
11. Liu, Z.Q. et al. (2014) Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis. PLoS One, 9, e87103.
12. Maréchal, R. et al. (2009) Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin. Cancer Res., 15, 2913-2919.
13. Elnaggar, M. et al. (2012) Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations. Curr. Pharm. Des., 18, 2811-2829.
14. Zheng, X. et al. (2015) Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature, 527, 525-530.
15. Skrypek, N. et al. (2015) The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. Oncotarget, 6, 10853-10867.
16. Bruns, C.J. et al. (1999) In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia, 1, 50-62.
17. Jesnowski, R. et al. (2005) Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by matrigel and N-acetylcysteine. Lab. Invest., 85, 1276-1291.
18. Hwang, R.F. et al. (2008) Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res., 68, 918-926.
19. Sparmann, G. et al. (2004) Generation and characterization of immortalized rat pancreatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol., 287, G211-G219.
20. Mathison, A. et al. (2010) Pancreatic stellate cell models for transcriptional studies of desmoplasia-associated genes. Pancreatology, 10, 505-516.
21. Ueda, Y. et al. (2004) Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J. Biol. Chem., 279, 24505-24513.
22. Liu, H. et al. (2008) Cysteine-rich protein 61 and connective tissue growth factor induce deadhesion and anoikis of retinal pericytes. Endocrinology, 149, 1666-1677.
23. Hasan, A. et al. (2011) The matricellular protein cysteine-rich protein 61 (CCN1/Cyr61) enhances physiological adaptation of retinal vessels and reduces pathological neovascularization associated with ischemic retinopathy. J. Biol. Chem., 286, 9542-9554.
24. Sanjana, N.E. et al. (2014) Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods, 11, 783-784.
25. Shalem, O. et al. (2014) Genome-scale CRISPR-Cas9 knockout screening in human cells. Science, 343, 84-87.
26. Badea, L. et al. (2008) Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology, 55, 2016-2027.
27. Crnogorac-Jurcevic, T. et al. (2013) Molecular analysis of precursor lesions in familial pancreatic cancer. PLoS One, 8, e54830.
28. Scarlett, C.J. et al. (2011) Precursor lesions in pancreatic cancer: morphological and molecular pathology. Pathology, 43, 183-200.
29. Moffitt, R.A. et al. (2015) Virtual microdissection identifies distinct tumor-and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet., 47, 1168-1178.
30. Mackey, J.R. et al. (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res., 58, 4349-4357.
31. Leask, A. et al. (2006) All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J. Cell Sci., 119, 4803-4810.
32. Haque, I. et al. (2011) Cyr61/CCN1 signaling is critical for epithelialmesenchymal transition and stemness and promotes pancreatic carcinogenesis. Mol. Cancer, 10, 8.
33. Duxbury, M.S. et al. (2004) RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene, 23, 1539-1548.
34. Xie, H. et al. (2013) Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer, 119, 173-181.
35. Nakahira, S. et al. (2007) Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int. J. Cancer, 120, 1355-1363.
36. König, J. et al. (2005) Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int. J. Cancer, 115, 359-367.
37. Nath, S. et al. (2013) MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. Oncogenesis, 2, e51.
38. Zhang, W. et al. (2013) Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets. Int. J. Oncol., 42, 1189-1196.
39. Long Q.Z. et al. (2013) Interaction of CCN1 with alphavbeta3 integrin induces P-glycoprotein and confers vinblastine resistance in renal cell carcinoma cells. Anticancer Drugs, 24, 810-817.
40. Erkan M. et al. (2012) The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance. Curr. Mol. Med., 12, 288-303.
41. Bachem, M.G. et al. (2005) Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology, 128, 907-921.
42. Yen, T.W. et al. (2002) Myofibroblasts are responsible for the desmoplastic reaction surrounding human pancreatic carcinomas. Surgery, 131, 129-134.
43. Apte, M.V. et al. (2004) Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas, 29, 179-187.
44. Jun, J.I. et al. (2011) Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat. Rev. Drug Discov., 10, 945-963.
45. Bartholin, L. et al. (2007) The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells. Cancer Lett., 246, 230-236.
46. Javle, M. et al. (2014) Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer. PLoS One, 9, e85942.
47. Hahn, S.A. et al. (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science, 271, 350-353.
48. Simeone, D.M. et al. (2000) Disruption of TGFbeta signaling pathways in human pancreatic cancer cells. Ann. Surg., 232, 73-80.
49. Rhim, A.D. et al. (2014) Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell, 25, 735-747.
50. Sherman, M.H. et al. (2014) Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell, 159, 80-93.
51. Özdemir, B.C. et al. (2014) Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell, 25, 719-734.
52. Provenzano, P.P. et al. (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell, 21, 418-429.
53. Melisi, D. et al. (2016) A phase II, double-blind study of galunisertib+gemcitabine (GG) vs gemcitabine+placebo (GP) in patients (pts) with unresectable pancreatic cancer (PC). 2016 ASCO Annual Meeting. J Clin Oncol, 34, abstract 4019.
54. Lamouille, S. et al. (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol., 15, 178-196.
55. Neesse, A. et al. (2013) CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc. Natl. Acad. Sci. USA, 110, 12325-12330.
56. Dimou, A. et al. (2013) Novel agents in the treatment of pancreatic adenocarcinoma. J. Pancreas, 14, 138-140.
57. Wang, Q. et al. (2011) Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis Tissue Repair, 4, 4.
58. Lin, M.T. et al. (2004) Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation. J. Biol. Chem., 279, 24015-24023.
59. Menendez, J.A. et al. (2005) A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene, 24, 761-779.
60. Long, X. et al. (2015) Stromal CYR61 confers resistance to mitoxantrone via spleen tyrosine kinase activation in human acute myeloid leukaemia. Br. J. Haematol., 170, 704-718.
61. Lee, K.B. et al. (2012) CYR61 controls p53 and NF-κB expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells. Cancer Lett., 315, 86-95.